News
-
-
-
COMMUNIQUÉ DE PRESSE
Le traitement pour l’acné vulgaire de Bausch Health, Canada Inc., (Pr)CABTREO(MC) (gel de phosphate de clindamycine, d’adapalène et de peroxyde de benzoyle), est maintenant couvert par les régimes publics de l’Ontario, de la Nouvelle Écosse et p
Bausch Health Canada lance CABTREO, un nouveau gel topique \/ acné vulgaire. Disponible via assurance-médicaments en Ontario, Nouvelle-Écosse et pour les Premières Nations. Traitement triple combinaison approuvé par Santé Canada -
COMMUNIQUÉ DE PRESSE
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
Bausch Health Canada Inc. launches CABTREO triple-combination gel for acne vulgaris, now accessible through public drug plans in Ontario, Nova Scotia, and federal government programs -
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Salix launches 'I Wish I Knew' campaign for Xifaxan, FDA-approved for hepatic encephalopathy. Advocating patient empowerment and education -
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health to Announce Second Quarter 2025 Results on July 30
Bausch Health Companies Inc. to release Q2 2025 financial results on July 30, 2025, followed by a conference call and webcast at 5:00 p.m. U.S. EDT. Details and materials available on the investor relations website
